Blockade of Epithelial Na+ Channels by Triamterenes - Underlying Mechanisms and Molecular Basis
Overview
Authors
Affiliations
The three subunits (alpha, beta, gamma) encoding for the rat epithelial Na+ channel (rENaC) were expressed in Xenopus oocytes, and the induced Na+ conductance was tested for its sensitivity to various triamterene derivatives. Triamterene blocked rENaC in a voltage-dependent manner, and was 100-fold less potent than amiloride at pH 7.5. At -90 mV and -40 mV, the IC50 values were 5 microM and 10 microM, respectively. The blockage by triamterene, which is a weak base with a pKa of 6.2, was dependent on the extracellular pH. The IC50 was 1 microM at pH 6.5 and only 17 microM at pH 8.5, suggesting that the protonated compound is more potent than the unprotonated one. According to a simple kinetic analysis, the apparent inhibition constants at -90 mV were 0.74 microM for the charged and 100.6 microM for the uncharged triamterene. The main metabolite of triamterene, p-hydroxytriamterene sulfuric acid ester, inhibited rENaC with an approximately twofold lower affinity. Derivatives of triamterene, in which the p-position of the phenylmoiety was substituted by acidic or basic residues, inhibited rENaC with IC50 values in the range of 0.1-20 microM. Acidic and basic triamterenes produced a rENaC blockade with a similar voltage and pH dependence as the parent compound, suggesting that the pteridinemoiety of triamterene is responsible for that characteristic. Expression of the rENaC alpha-subunit-deletion mutant, Delta278-283, which lacks a putative amiloride-binding site, induced a Na+ channel with a greatly reduced affinity for both triamterene and amiloride. In summary, rENaC is a molecular target for triamterene that binds to its binding site within the electrical field, preferably as a positively charged molecule in a voltage- and pH-dependent fashion. We propose that amiloride and triamterene bind to rENaC using very similar mechanisms.
Epithelial Na Channels Function as Extracellular Sensors.
Kashlan O, Wang X, Sheng S, Kleyman T Compr Physiol. 2024; 14(2):1-41.
PMID: 39109974 PMC: 11309579. DOI: 10.1002/cphy.c230015.
Isaeva V, Vedenyapina M, Kurmysheva A, Weichgrebe D, Nair R, Nguyen N Molecules. 2021; 26(21).
PMID: 34771037 PMC: 8587771. DOI: 10.3390/molecules26216628.
DArcangelo D, Scatozza F, Giampietri C, Marchetti P, Facchiano F, Facchiano A Cancers (Basel). 2019; 11(4).
PMID: 30934896 PMC: 6520727. DOI: 10.3390/cancers11040446.
Modulatory effects of hydrochlorothiazide and triamterene on resistant hypertension patients.
Gong H, Li Y, Zheng C, Du T, Luo B, Pang M Exp Ther Med. 2017; 13(6):3217-3222.
PMID: 28588673 PMC: 5450789. DOI: 10.3892/etm.2017.4412.
Li Y, Cheng K, Niu C, Lo S, Cheng J, Niu H Drug Des Devel Ther. 2017; 11:1127-1134.
PMID: 28435224 PMC: 5391213. DOI: 10.2147/DDDT.S131892.